Cardiometabolic outcomes in Kronos Early Estrogen Prevention Study continuation: 14-year follow-up of a hormone therapy trial
Kantarci K, Tosakulwong N, Lesnick T, Kara F, Kendall-Thomas J, Kapoor E, Fields J, James T, Lobo R, Manson J, Pal L, Hammers D, Malek-Ahmadi M, Cedars M, Naftolin F, Santoro N, Miller V, Harman S, Dowling N, Gleason C. Cardiometabolic outcomes in Kronos Early Estrogen Prevention Study continuation: 14-year follow-up of a hormone therapy trial. Menopause The Journal Of The North American Menopause Society 2023, 31: 10-17. PMID: 37989141, PMCID: PMC10756493, DOI: 10.1097/gme.0000000000002278.Peer-Reviewed Original ResearchConceptsKronos Early Estrogen Prevention StudyOral conjugated equine estrogenConjugated equine estrogensBetter cardiovascular healthHormone therapyEquine estrogensInsulin resistanceMenopausal womenCardiovascular healthClinical trialsHormone therapy trialsPerson clinic visitsDiastolic blood pressureHomeostasis model assessmentSelf-reported diabetesYears of onsetMultisite clinical trialLevels of glucoseMicronized progesteroneDiabetes medicationsStudy of participantsCardiometabolic effectsCardiometabolic outcomesClinic visitsBlood pressure